company background image
JSPR

Jasper Therapeutics NasdaqCM:JSPR Stock Report

Last Price

US$3.13

Market Cap

US$118.6m

7D

5.4%

1Y

-68.4%

Updated

24 May, 2022

Data

Company Financials +
JSPR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

JSPR Stock Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

Jasper Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Jasper Therapeutics
Historical stock prices
Current Share PriceUS$3.13
52 Week HighUS$18.88
52 Week LowUS$2.45
Beta0.51
1 Month Change23.72%
3 Month Change-17.96%
1 Year Change-68.45%
3 Year Changen/a
5 Year Changen/a
Change since IPO-68.13%

Recent News & Updates

Shareholder Returns

JSPRUS BiotechsUS Market
7D5.4%-3.2%-4.0%
1Y-68.4%-22.1%-13.2%

Return vs Industry: JSPR underperformed the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: JSPR underperformed the US Market which returned -12.3% over the past year.

Price Volatility

Is JSPR's price volatile compared to industry and market?
JSPR volatility
JSPR Average Weekly Movement13.9%
Biotechs Industry Average Movement12.4%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: JSPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: JSPR's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a34Ron Martellhttps://jaspertherapeutics.com

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company’s lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Jasper Therapeutics Fundamentals Summary

How do Jasper Therapeutics's earnings and revenue compare to its market cap?
JSPR fundamental statistics
Market CapUS$118.55m
Earnings (TTM)-US$23.09m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JSPR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$23.09m
Earnings-US$23.09m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did JSPR perform over the long term?

See historical performance and comparison

Valuation

Is Jasper Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.74x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate JSPR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate JSPR's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: JSPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.

PE vs Market: JSPR is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate JSPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: JSPR is overvalued based on its Price-To-Book Ratio (1.7x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Jasper Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-15.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JSPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: JSPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: JSPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: JSPR is forecast to have no revenue next year.

High Growth Revenue: JSPR is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: JSPR is forecast to be unprofitable in 3 years.


Past Performance

How has Jasper Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


42.3%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: JSPR is currently unprofitable.

Growing Profit Margin: JSPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if JSPR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare JSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JSPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: JSPR has a negative Return on Equity (-33.9%), as it is currently unprofitable.


Financial Health

How is Jasper Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: JSPR's short term assets ($73.8M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: JSPR's short term assets ($73.8M) exceed its long term liabilities ($6.5M).


Debt to Equity History and Analysis

Debt Level: JSPR is debt free.

Reducing Debt: JSPR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: JSPR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: JSPR has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 68.4% each year.


Dividend

What is Jasper Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate JSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JSPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JSPR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as JSPR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Ron Martell (59 yo)

0.17

Tenure

Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics since March 15, 2022. He has been the President, Chief Executive Officer, Chief Fina...


Leadership Team

Experienced Management: JSPR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: JSPR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Jasper Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Jasper Therapeutics, Inc.
  • Ticker: JSPR
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$118.553m
  • Shares outstanding: 37.88m
  • Website: https://jaspertherapeutics.com

Number of Employees


Location

  • Jasper Therapeutics, Inc.
  • 2200 Bridge Pkwy
  • Suite 102
  • Redwood City
  • California
  • 94065
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.